|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-1-9
|
|
pubmed:abstractText |
OSI-7904L is a liposomal formulation of a potent thymidylate synthase (TS) inhibitor. This phase I study evaluated the safety, tolerability and pharmacokinetics (PK) of OSI-7904L administered in combination with oxaliplatin every 21 days in patients with advanced colorectal carcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/((S)-2-(5-(1,2-dihydro-3-methyl-1-ox...,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Glutarates,
http://linkedlifedata.com/resource/pubmed/chemical/Isoindoles,
http://linkedlifedata.com/resource/pubmed/chemical/Liposomes,
http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/Thymidylate Synthase,
http://linkedlifedata.com/resource/pubmed/chemical/oxaliplatin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0344-5704
|
|
pubmed:author |
pubmed-author:ChickJJ,
pubmed-author:ClampA RAR,
pubmed-author:DeboisMM,
pubmed-author:EORTC New Drug Development Group,
pubmed-author:GovaertsA-SAS,
pubmed-author:JaysonG CGC,
pubmed-author:LacombeDD,
pubmed-author:MarreaudSS,
pubmed-author:SchöffskiPP,
pubmed-author:TwelvesCC,
pubmed-author:ValleJ WJW,
pubmed-author:WilsonR HRH
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
61
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
579-85
|
|
pubmed:meshHeading |
pubmed-meshheading:17520255-Aged,
pubmed-meshheading:17520255-Antineoplastic Agents,
pubmed-meshheading:17520255-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17520255-Colorectal Neoplasms,
pubmed-meshheading:17520255-Dose-Response Relationship, Drug,
pubmed-meshheading:17520255-Enzyme Inhibitors,
pubmed-meshheading:17520255-Female,
pubmed-meshheading:17520255-Glutarates,
pubmed-meshheading:17520255-Humans,
pubmed-meshheading:17520255-Isoindoles,
pubmed-meshheading:17520255-Liposomes,
pubmed-meshheading:17520255-Male,
pubmed-meshheading:17520255-Middle Aged,
pubmed-meshheading:17520255-Organoplatinum Compounds,
pubmed-meshheading:17520255-Pharmacogenetics,
pubmed-meshheading:17520255-Polymorphism, Genetic,
pubmed-meshheading:17520255-Quinazolines,
pubmed-meshheading:17520255-Thymidylate Synthase
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer.
|
|
pubmed:affiliation |
Cancer Research UK and University of Manchester Department of Medical Oncology, Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK. Andrew.Clamp@christie.nhs.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
